DOP2004001024A - Compuestos de pirazolilo e imidazolilo biciclicos y usos de los mismos - Google Patents

Compuestos de pirazolilo e imidazolilo biciclicos y usos de los mismos

Info

Publication number
DOP2004001024A
DOP2004001024A DO2004001024A DO2004001024A DOP2004001024A DO P2004001024 A DOP2004001024 A DO P2004001024A DO 2004001024 A DO2004001024 A DO 2004001024A DO 2004001024 A DO2004001024 A DO 2004001024A DO P2004001024 A DOP2004001024 A DO P2004001024A
Authority
DO
Dominican Republic
Prior art keywords
compounds
pirazolilo
imidazolilo
bicycle
same
Prior art date
Application number
DO2004001024A
Other languages
English (en)
Inventor
Philip Albert Carpino
Robert Lee Dow
David Andrew Griffith
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of DOP2004001024A publication Critical patent/DOP2004001024A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En este documento se describen compuestos de formula (I) Se ha demostrado que los compuestos actúan como ligando de receptores de canabinoides y, por lo tanto, son útiles en el tratamiento de enfermedades asociadas con la mediación de los receptores de canabinoides en animales.
DO2004001024A 2003-11-07 2004-11-03 Compuestos de pirazolilo e imidazolilo biciclicos y usos de los mismos DOP2004001024A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51828003P 2003-11-07 2003-11-07

Publications (1)

Publication Number Publication Date
DOP2004001024A true DOP2004001024A (es) 2005-05-14

Family

ID=34572986

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2004001024A DOP2004001024A (es) 2003-11-07 2004-11-03 Compuestos de pirazolilo e imidazolilo biciclicos y usos de los mismos

Country Status (29)

Country Link
US (2) US7151097B2 (es)
EP (1) EP1682554A1 (es)
JP (2) JP4056549B2 (es)
KR (1) KR20060086396A (es)
CN (1) CN1886407A (es)
AP (1) AP2006003601A0 (es)
AR (1) AR046831A1 (es)
AU (1) AU2004286909A1 (es)
BR (1) BRPI0416299A (es)
CA (1) CA2544752A1 (es)
CR (1) CR8387A (es)
DO (1) DOP2004001024A (es)
EA (1) EA009742B1 (es)
EC (1) ECSP066549A (es)
GT (1) GT200400226A (es)
HR (1) HRP20060166A2 (es)
IL (1) IL175283A0 (es)
IS (1) IS8426A (es)
MA (1) MA28151A1 (es)
MX (1) MXPA06005023A (es)
NL (1) NL1027434C2 (es)
NO (1) NO20062618L (es)
OA (1) OA13280A (es)
PA (1) PA8616801A1 (es)
PE (1) PE20050576A1 (es)
TN (1) TNSN06129A1 (es)
TW (2) TW200716135A (es)
WO (1) WO2005044822A1 (es)
ZA (1) ZA200603594B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
EP1603585A2 (en) * 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
KR20070051921A (ko) * 2004-09-27 2007-05-18 화이자 프로덕츠 인코포레이티드 이환 피라졸릴 화합물의 제조 방법
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
JP2008536909A (ja) * 2005-04-20 2008-09-11 ファイザー・プロダクツ・インク カンナビノイド受容体リガンドとしてのアシルアミノ二環複素芳香族化合物
WO2006129193A2 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
WO2007046550A1 (en) * 2005-10-21 2007-04-26 Mitsubishi Tanabe Pharma Corporation Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity
WO2007060525A2 (en) 2005-11-28 2007-05-31 Pfizer Products Inc. Process for preparing bicyclic pyrazolyl and imidazolyl compounds
US8138188B2 (en) * 2006-02-23 2012-03-20 Pfizer Inc. Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
WO2007132841A1 (ja) * 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
WO2008048648A2 (en) * 2006-10-17 2008-04-24 Acadia Pharmaceuticals Inc. Cb1-modulating compounds and their use
CA2669311C (en) 2006-11-13 2011-09-20 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
WO2009032754A2 (en) * 2007-08-31 2009-03-12 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
CA2731897C (en) * 2008-08-06 2013-07-02 Pfizer Limited Diazepine and diazocane compounds as mc4 agonists
US9549006B2 (en) * 2013-07-31 2017-01-17 Cisco Technology, Inc. Self-adaptive sample period for content sharing in communication sessions
DK3066085T3 (da) * 2013-11-08 2020-06-02 Incyte Holdings Corp Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor
US11191814B2 (en) 2018-09-04 2021-12-07 Paw Power, Inc. Pet food formulation with cannabinoids
US11504416B2 (en) 2018-09-04 2022-11-22 Paw Power, Inc. Formulation with cannabinoids
KR20220044738A (ko) * 2019-08-09 2022-04-11 니혼노야쿠가부시키가이샤 옥사제피논 유도체, 이 유도체를 함유하는 농원예용 살충제, 및 그의 사용방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
JP2005507875A (ja) 2001-08-31 2005-03-24 ユニバーシティ オブ コネチカット カンナビノイド受容体に作用する新規なピラゾール類似体
ES2252524T3 (es) 2001-09-24 2006-05-16 Bayer Pharmaceuticals Corporation Preparacion y uso de derivados de 1,5,6,7-tetrahidropirrolo(3,2-c)piridina para el tratamiento de la obesidad.
GB0207249D0 (en) 2002-03-27 2002-05-08 Glaxo Group Ltd Novel compounds
CA2502511A1 (en) * 2002-10-18 2004-05-29 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
WO2004098520A2 (en) 2003-05-01 2004-11-18 Irm Llc Compounds and compositions as protein kinase inhibitors
MXPA05011922A (es) * 2003-05-07 2006-02-17 Pfizer Prod Inc Ligandos del receptor de cannabinoides y sus usos.
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20050026983A1 (en) 2003-07-30 2005-02-03 Pfizer Inc Imidazole compounds and uses thereof
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
KR20070051921A (ko) * 2004-09-27 2007-05-18 화이자 프로덕츠 인코포레이티드 이환 피라졸릴 화합물의 제조 방법

Also Published As

Publication number Publication date
US20070027133A1 (en) 2007-02-01
IS8426A (is) 2006-04-21
OA13280A (en) 2007-01-31
AP2006003601A0 (en) 2006-04-30
JP2007302685A (ja) 2007-11-22
HRP20060166A2 (en) 2006-10-31
AU2004286909A1 (en) 2005-05-19
JP4056549B2 (ja) 2008-03-05
US7151097B2 (en) 2006-12-19
PE20050576A1 (es) 2005-09-14
KR20060086396A (ko) 2006-07-31
IL175283A0 (en) 2006-09-05
MXPA06005023A (es) 2006-07-06
EP1682554A1 (en) 2006-07-26
JP2007510707A (ja) 2007-04-26
MA28151A1 (fr) 2006-09-01
TW200716135A (en) 2007-05-01
ZA200603594B (en) 2007-09-26
TW200526669A (en) 2005-08-16
NL1027434A1 (nl) 2005-05-10
GT200400226A (es) 2005-09-06
ECSP066549A (es) 2006-10-17
NL1027434C2 (nl) 2007-11-27
WO2005044822A1 (en) 2005-05-19
BRPI0416299A (pt) 2007-01-23
EA200600647A1 (ru) 2006-10-27
AR046831A1 (es) 2005-12-28
PA8616801A1 (es) 2006-05-16
CR8387A (es) 2007-05-30
CN1886407A (zh) 2006-12-27
TNSN06129A1 (fr) 2007-11-15
NO20062618L (no) 2006-08-07
TWI280245B (en) 2007-05-01
US20050101592A1 (en) 2005-05-12
CA2544752A1 (en) 2005-05-19
EA009742B1 (ru) 2008-04-28

Similar Documents

Publication Publication Date Title
DOP2004001024A (es) Compuestos de pirazolilo e imidazolilo biciclicos y usos de los mismos
UY28275A1 (es) Ligandos de receptores de cannabinoides y sus usos
ECSP055945A (es) Compuestos de pirazolotriazina y usos de los mismos
ECSP056117A (es) Ligandos de receptores de cannabinoides y sus usos
UY28278A1 (es) Ligandos del receptor cannabinoide y usos de los mismos
UY28044A1 (es) Compuestos de purina y usos de los mismos
ECSP056116A (es) Ligandos del receptor cannabinoide y usos de los mismos
HN2003000094A (es) Indazoles subtituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.
UY29478A1 (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
CR9113A (es) Compuestos acetamida como fungicidas
ECSP067121A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CR9777A (es) Derivados fungicidas de fenilamidina con piridiniloxi
CR8744A (es) Compuestos terapeuticos
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
NI200600094A (es) Compuesto heterociclicos fusionados
HN2003000416A (es) Derivados de pirrolopirimidina
ECSP10010014A (es) Derivados de 2-alquiltio-2-quinoliniloxi-acetamida como fungicidas
CR9260A (es) COMPUESTOS DE BIS ARILO Y HETEROARILO SUSTITUIDOS COMO ANTAGONISTAS SELECTIVOS DE 5HT2a
ECSP088527A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CR10637A (es) Fungicidas
UY28981A1 (es) Nuevos plaguicidas
GT200400188A (es) 5-arilpirimidinas como agentes anticancerigenos
UY28599A1 (es) Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos
UY28983A1 (es) Agentes plaguicidas
DOP2004000884A (es) Ligandos de receptores de cannabinoides y sus usos